Our Team

Mr. Will Wonhyung Park

Founder & Chief Executive Officer
Mr. Park has been leading the executive management and commercial affairs of TSG since its establishment in 2016. He has extensive experience in the finance industry, building and leading several business groups across Asia on behalf of global investment banks. Prior to TSG, he was Managing Director and Head of the Strategic Investment Group at Deutsche Bank Group in Japan. He is a graduate of Boston University’s School of Management.

Dr. Patricia Fast, M.D., Ph.D.

Chief Technology Officer
Dr. Fast has been working to solve global concerns of viral infectious diseases for over 30 years. She had served multiple leading roles with international governmental organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) where she oversaw early HIV vaccine trials.

At International AIDS Vaccine Initiative (IAVI), as Chief Medical Officer, she oversaw 28 clinical trials; including HIV, Yellow Fever, and Hepatitis B vaccines. In addition, she held industry positions at Aviron (now Medimmune/AstraZeneca), where she was responsible for studies of live attenuated intranasal Influenza vaccine (now licensed) and live attenuated Cytomegalovirus vaccine. She was also seconded to the World Health Organization in 2014-15 to assist with Ebola vaccine trials in response to the outbreak.

Dr. Fast currently holds an adjunct clinical associate professorship at Stanford University School of Medicine and serves as senior technical advisor for IAVI, for epidemiology and product clinical development. She is an Academic Editor for PLOS One and has published nearly 100 papers in peer reviewed journals.

Dr. Emily Wood Carrow, Ph.D.

Scientific Program Director
Dr. Carrow has extensive experience in the field of Infectious Diseases. She has held scientific managerial positions in the U.S. and Europe, including the U.S. Food and Drug Administration, the San Raffaele Scientific Institute in Milan, Italy, Sorin Biomedica in Saluggia, Italy, The World Foundation for AIDS Research and Prevention in Paris (founded by Professor Luc Montagnier, co-discoverer of HIV), DuPont Pharmaceuticals and the International AIDS Vaccine Initiative in New York. More recently, as Vice President of Research and Development at Advanced BioAdjuvants LLC, Dr. Carrow was instrumental to the success development of a novel vaccine adjuvant from the discovery stage to the clinic.

She has practical experience in basic scientific research, process development, regulatory affairs, program management, research administration and business development and is recognized as a driving force behind many successful collaborations and partnerships in business, non-profit, and government settings.

Dr. Carrow received her B.S. in Biology With Distinction from the George Washington University, her M.S. in Botany from the University of Rhode Island and her Ph.D. in Microbiology and Immunology from Tulane University. She is a member of Phi Beta Kappa.

Ms. Yvonne Eng

Business Manager
Ms. Eng is responsible for the operational affairs of TSG. She has 20 years of experience as an analyst and project manager in the IT healthcare industry, focusing on innovative healthcare solutions and supporting clinicians in research and education. She had worked closely with clinical and non-clinical staff to conduct trials and implement research and learning systems in some of Singapore’s public hospitals. She is a graduate of National University of Singapore.

Dr. Sven Enterlein, Ph.D.

Consulting Scientist
Dr. Enterlein has over 10 years of experience in antiviral drug development and coordinating preclinical studies. Previously, he was the Associate Director of Antiviral Services at Integrated BioTherapeutics and Program Director at TSG Therapeutics. He received his Ph.D. in human biology and virology from Philipps University of Marburg, and then completed postdoctoral research at the University of Texas Medical Branch, Galveston and the U.S. Army Medical Research Institute of Infectious Diseases.

Dr. Nancy C. Motola, Ph.D., RAC,

Consulting Scientist
Dr. Motola has extensive experience in the Pharmaceutical Industry, encompassing both small molecules and biologics, in many therapeutic areas; in regulatory affairs and quality assurance, as well as chemical development/manufacturing.

She has held many leadership roles in pharmaceutical companies. In these roles, she was part of the management team, built and managed the product compliance organization, and was responsible for the approvals of drug products such as Soliris, a monoclonal antibody for a rare hematological condition and other rare diseases, and Durlaza, a controlled release aspirin product for secondary prevention of acute cardiac events. In Regulatory Affairs, Dr. Motola had achieved approvals of several marketed products at Bayer Corp., Abbott Laboratories, and E.R. Squibb & Sons, Inc. where she also started her career as a process chemist.

She received her PhD and MS degrees in Medicinal Chemistry from University of Rhode Island College of Pharmacy; and is Regulatory Affairs Certified (RAC). She is also a member of various Scientific Advisory Boards and a founder & past chair of the Regulatory Sciences Section of the American Association of Pharmaceutical Scientists (AAPS), and a frequent contributor to industry and educational programs.

Mr. Jim Ackland

Consulting Specialist
Mr. Ackland has extensive experience in the manufacture, quality control, development and international regulatory requirements for pharmaceutical products. This includes senior management positions in the manufacture, quality assurance and research and development at CSL Limited, Australia. He was formerly Head of Regulatory Affairs for Vaccine Products at CSL Limited (Australia) and subsequently, he was Vice President/Senior Consultant for the Biologics Consulting Group (USA), an internationally recognized pharmaceutical regulatory consulting company. Since 2005, he has been providing regulatory and product development advice and assistance to pharmaceutical and biotech companies.

Mr. Ackland has been involved in many pharmaceutical development projects as the lead regulatory advisor/negotiator and preclinical safety expert. He has filed numerous successful clinical trial applications in the US, Europe and in Australia.

Dr. Ehsan S. Yazdi Ph.D., MPH

Scientific Advisor
Dr. Yazdi is the Founder, Board Director and Chief Executive Officer of NomoCan Pharmaceuticals, an oncology drug development company based in New York City. Prior to starting NomoCan, he was an Assistant Professor and translational research principle investigator at the Division of Gynecologic Oncology, State University of New York, Downstate Medical Center. As a cancer-geneticist and molecular biologist, he has extensive experience in the field of cancer biomarker discovery and therapeutics. He is co-inventor on multiple issued and pending patent applications and has published in leading journals such as Proceedings of the National Academy of Sciences (PNAS), Annals of Surgical Oncology and Translational Research to name a few. His research has been recognized by various awards including “Outstanding Clinical Scholar” award from the AACR/GlaxoSmithKline as well as by the Robert Furchgott Society.

Mr. Anthony Flynn

Senior Advisor
Mr. Flynn has an extensive background in resource mobilization in support of global health initiatives and institutions.  He has served as Director of Development at the International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b) in Bangladesh; as Deputy Director General of the International Vaccine Institute in Seoul, Korea; and as Head of Development at the International AIDS Society in Geneva, Switzerland.  He also supported the resource mobilization programs of a leading public-private global health partnership, the International AIDS Vaccine Initiative (IAVI) where he served as Manager of Development at IAVI’s European headquarters.  Previously, he worked for a number of educational, scientific and cultural organizations in the United States, including the New York Public Library, the American Museum of Natural History and Lincoln Center for the Performing Arts. Mr. Flynn has a BA and MA from the University of Dublin, Trinity College.